Perion Network (PERI) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.26 per share a year ago.

PowerFleet (AIOT) came out with quarterly earnings of $0.01 per share, in line with the Zacks Consensus Estimate . This compares to a loss of $0.21 per share a year ago.

Seeking Alpha notes that S&P 500 gains are concentrated in 10 mega-cap tech stocks, highlighting weak market breadth and under-performance in many other sectors. Key laggards include Gartner, Charter Communications, Fortinet, Novo Nordisk, Trade Desk, Chipotle, and Vertex, each facing sector-specific headwinds. Healthcare, IT services, and communications stocks are pressured by competition, slowing growth, and sector-wide bearish sentiment; value opportunities exist but risks remain.

Investors love dividend stocks, especially those with high yields, because they provide a substantial income stream and offer significant total return potential.

CHEYENNE, WY, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Next Technology Holding Inc. (NASDAQ: NXTT) (the "Company") today announced the formal approval of a Dividend Policy ("Policy") requiring annual dividend distributions of no less than 80% of profits attributable to owners, which is set to take effect on September 8, 2025. This strategic commitment follows unanimous Board approval via written consent and is underpinned by the Company's robust Q2 2025 net income of US$312 million.

CHEYENNE, Wyo., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Next Technology Holding Inc. (“NXTT” or the “Company”) (NASDAQ: NXTT), a technology firm committed to delivering AI-enabled software development services and strategic Bitcoin acquisition, today announced its financial results for the six-month period ended June 30, 2025.

DENVER--(BUSINESS WIRE)--Ibotta, Inc. (NYSE: IBTA), which operates the largest digital promotions network in North America, today announced the appointment of industry leader, Matt Puckett, as its new Chief Financial Officer (CFO), effective August 25. Puckett will lead Ibotta's financial strategy and operations, and investor relations as the Company continues its commitment to innovation in performance marketing for CPGs. "We are thrilled to welcome Matt to the Ibotta executive team," said Bry.

C3.ai shares were set for heavy losses on Monday, falling by more than 31% after the artificial intelligence software maker warned that its latest quarterly results would fall far short of expectations. The company's preliminary figures for the July quarter revealed revenue of around $70.3 million — roughly 33% below its previous guidance.

You can catch Warrior Money on Apple Podcasts, Spotify, Amazon Music, or wherever you get your podcasts. The future of war and work is tech, and veterans are in demand for high-paying tech careers.

Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.27 per share a year ago.

Aaon (AAON) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.62 per share a year ago.

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23.

International Money Express (IMXI) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.55 per share a year ago.

CINCINNATI , Aug. 11, 2025 /PRNewswire/ -- The Kroger Co. (NYSE: KR) today announced a settlement with C&S Wholesale Grocers, LLC, regarding previously pending litigation between the parties in the Superior Court for the State of Delaware. All claims have been resolved.

MSDL's Q2 earnings disappointed, with declining NAV, weak dividend coverage, and rising non-accruals signaling fundamental portfolio issues. Despite a tempting 11% yield and deep discount to NAV, I see the discount as a reflection of ongoing risks, not a buying opportunity. Management struggles to deploy capital into new investments, and net investment income barely covers the dividend, leaving little margin for error.

Strategic Partnership Expands International Reach, Monetizes Technology at Scale, and Creates Long-Term Shareholder Value New York, New York--(Newsfile Corp. - August 11, 2025) - DigiAsia Corp (NASDAQ: FAAS) ("DigiAsia" or the "Company"), a Southeast Asia leader in B2B API-based payments for fintech and digital services, today announced that its wholly owned subsidiary DigiAsia Bios Pte Ltd has entered into a $6 million AI platform licensing agreement with Nowigence Inc. for exclusive rights in the Middle East and North Africa (MENA) and North American markets. Under the agreement, Nowigence will issue 1,200,000 Class A common shares to DigiAsia in exchange for …

SUNNYVALE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2025 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session.

- Dr. Richard Kenney, Chief Medical Officer of Sonnet, discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221)

MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Wrap Technologies, Inc. (NASDAQ: WRAP) (“Wrap” or the “Company”), a recognized innovator in public safety technology, today announced the full launch of WrapVision, its next-generation, all-in-one body-worn camera platform. WrapVision is fully compliant with the Trade Agreements Act (“TAA”) and is a North American–made solution engineered to meet the growing compliance, performance, and transparency demands of law enforcement, public safety, and healthcare professionals across the United States.

Extends Patent Protection Through December 2041 ART27.13 is Currently under Evaluation in a Phase 2 Study for the Treatment of Cancer-Related Anorexia SOLANA BEACH, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the European Patent Office (EPO) has issued a Notice of Allowance for Artelo's European patent application No.